TNF inhibitors – Mechanisms of action, approved and off-label indications
- 1 October 2014
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pharmacological Reports
- Vol. 66 (5), 836-844
- https://doi.org/10.1016/j.pharep.2014.05.004
Abstract
Tumor necrosis factor inhibitors (TNFi) belong to the group of biologic drugs, holding presently top positions on lists of most profitable products for pharmaceutical companies. Although current indications for TNFi include only selected diseases with an established role of immune dysfunction in their pathogenesis, studies on new indications are being carried out all over the world. The most important aspect of TNFi therapy is a targeted therapeutic approach, allowing to avoid a wide range of side effects associated with treatment with nonspecific immunosuppressive agents. Results of the trials on TNFi in the approved indications are widely accessible and analyzed elsewhere, both in primary publications as well as in systematic reviews and meta-analyses. Here we aim to discuss their mechanisms of action, and approved, as well as off-label indications of TNFi. In addition, we present comprehensive evidence on TNFi in treatment of rheumatoid arthritis (RA); the first authorized and probably most extensively developed indication for the majority of TNFi.Keywords
Funding Information
- European Union – The European Regional Development Fund
This publication has 71 references indexed in Scilit:
- Higher serum levels of tumour necrosis factor and its soluble receptors are associated with ovarian tumoursVideosurgery and Other Miniinvasive Techniques, 2012
- Tumor necrosis factor-α increases brain-derived neurotrophic factor expression in trigeminal ganglion neurons in an activity-dependent mannerNeuroscience, 2011
- Tumor necrosis factor receptor cross‐talkThe FEBS Journal, 2011
- Tooth pulp inflammation increases brain-derived neurotrophic factor expression in rodent trigeminal ganglion neuronsNeuroscience, 2010
- Is there any correlation between TNF-related apoptosis-inducing ligand (TRAIL) genetic variants and breast cancer?Videosurgery and Other Miniinvasive Techniques, 2010
- Clinical research Tumour necrosis factor gene polymorphisms and migraine in Greek childrenVideosurgery and Other Miniinvasive Techniques, 2010
- Original research Do soluble p55 and p75 TNF- receptor concentrations play a role in women with primary sterility?Videosurgery and Other Miniinvasive Techniques, 2010
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995
- Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxinNature, 1984
- An endotoxin-induced serum factor that causes necrosis of tumors.Proceedings of the National Academy of Sciences of the United States of America, 1975